CNS Pharmaceuticals (NASDAQ:CNSP) Receives Hold Rating from Maxim Group

Maxim Group reaffirmed their hold rating on shares of CNS Pharmaceuticals (NASDAQ:CNSP) in a research report released on Tuesday morning,Benzinga reports.

Separately, Alliance Global Partners raised shares of CNS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 24th.

CNS Pharmaceuticals Stock Down 51.8 %

Shares of CNS Pharmaceuticals stock opened at $1.63 on Tuesday. The firm has a market cap of $1.87 million, a PE ratio of -0.02 and a beta of 2.65. CNS Pharmaceuticals has a twelve month low of $1.28 and a twelve month high of $975.00. The business has a 50-day moving average price of $4.10 and a 200 day moving average price of $5.43.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wealthfront Advisers LLC acquired a new position in shares of CNS Pharmaceuticals during the fourth quarter valued at approximately $26,000. Integrated Wealth Concepts LLC purchased a new stake in shares of CNS Pharmaceuticals during the fourth quarter worth approximately $30,000. Connective Capital Management LLC acquired a new position in CNS Pharmaceuticals in the 4th quarter valued at $34,000. XTX Topco Ltd purchased a new position in CNS Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Citadel Advisors LLC acquired a new stake in CNS Pharmaceuticals during the 4th quarter worth $39,000. 14.02% of the stock is owned by hedge funds and other institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.